3:38 PM
Jun 13, 2018
 |  BC Extra  |  Company News

Management tracks: Salk Institute, Galectin

The Board of Trustees for the Salk Institute for Biological Studies (La Jolla, Calif.) said that cancer and gene therapy researcher Inder Verma has resigned. The institute had placed Verma on administrative leave in April pending investigation following allegations of sexual harassment.

Allergy company Aimmune Therapeutics Inc. (NASDAQ:AIMT) hired Jayson Dallas as president and CEO. He was chief commercial officer at Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE).

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said Luc Debruyne will step down as president of its vaccines unit at year end. He will be succeeded by Roger Connor, president of GSK's global manufacturing and supply unit, effective September 1.

TiGenix N.V. (Euronext:TIG; NASDAQ:TIG) said effective June 15, Eduardo Bravo will step down as CEO of the stem cell company, which Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) is acquiring. Bravo becomes chairman of the board of gene therapy company Vivet Therapeutics (Paris, France). Takeda Senior Director Sebastian Wehle and TiGenix CFO Claudia D’Augusta will be in charge of daily management of TiGenix operations during the integration.

Chronic liver and skin disease and cancer company Galectin Therapeutics Inc. (NASDAQ:GALT) said President, CEO and CMO Peter Traber will resign, effective July 6. COO Harold Shlevin will succeed as president and CEO.

Neurology company Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) hired Daniel Brennan as chief commercial officer. He was COO at Edge Therapeutics Inc. (NASDAQ:EDGE).

Cancer immunotherapy company Arcus Biosciences Inc. (NYSE:RCUS) promoted CBO and CFO Jennifer Jarrett to COO and CFO.

Hematology company Imara Inc. (Cambridge, Mass.) said President and CEO James McArthur will step down. He is succeeded by Rahul Ballal as CEO. Ballal was CBO at Northern Biologics Inc. (Toronto, Canada) and an entrepreneur-in-residence at Versant Ventures.

Diagnostics company Metabolon Inc. (Morrisville, N.C.) said President and CEO John Ryals has retired. He is succeeded by CBO Rohan Hastie.

Microbiome company Finch Therapeutics Group Inc. (Somerville, Mass.) hired Ulrich Thienel as CMO and Gregory Perry as CFO. Thienel was chief development and medical officer at RRD International LLC (Rockville, Md.) and Perry was chief financial and administrative officer at Novelion Therapeutics Inc. (NASDAQ:NVLN).

Cancer immunotherapy company Lytix Biopharma A/S (Tromso, Norway) hired Hamina Patel as CMO. She was director of drug development, oncology at Johnson & Johnson (NYSE:JNJ).

Cancer company H3 Biomedicine Inc. (Cambridge, Mass.) said Chief Data Sciences Officer Lihua Yu will serve as president.

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD